ArticleJournal of clinical medicine2026

Real-World Effectiveness, Safety, and 36-Month Persistence of Upadacitinib in Elderly Patients with Moderate-to-Severe Atopic Dermatitis: The 3-6 Month Critical Window and the Role of Early Itch Response and Psychotropic Medication Use.

Yaoyao Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.